MLICM
IBIO icon

Metropolitan Life Insurance Company (MetLife)’s iBio IBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126
Closed -$66.7K – 2804
2021
Q3 		$66.7K Buy
+126
New +$78.5K ﹤0.01% 2715
2021
Q2 		– Sell
-120
Closed -$92.7K – 2778
2021
Q1 		$92.7K Buy
+120
New +$105K ﹤0.01% 2448

Other funds holding IBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IBIO Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of iBio (IBIO) in Q4 2021, closing a stake of 126 shares — an estimated $66.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IBIO in Q1 2021 and held it in 2 quarters. The position peaked at $92.7K in Q1 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 126 iBio shares in Q4 2021, an estimated $66.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in iBio in Q1 2021 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s iBio position peaked at $92.7K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.